Le Lézard
Classified in: Science and technology
Subject: ACC

Repurchase of Truecaller B shares in week 13, 2024


STOCKHOLM, April 2, 2024 /PRNewswire/ -- During 25 March 2024 and 28 March 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 136,717 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.

The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held in May 2024, and is carried out in accordance "Emittentregelverket".

On the Annual General Meeting 2023 the Board was authorized to buy back B-shares up until the Annual General Meeting in 2024. The new authorization means that buybacks may be made so that the company's shareholding does not exceed ten (10) percent of the total number of shares in the company outstanding as of the date of the annual general meeting.

Date:

Aggregated daily
volume (number of shares)
:

Weighted average share
price per day (SEK):

Total daily transaction
value (SEK):

25 March 2024

60 000

29.97

1 798 278

26 March 2024




27 March 2024

51 620

31.93

1 648 139

28 March 2024

25 097

32.23

808 919





Total accumulated over week 13/2024

136 717

31.125

4 255 336

Total accumulated during the buyback program

14 622 792

31.79

464 822 471

All acquisitions have been carried out on Nasdaq Stockholm by Carnegie on behalf of Truecaller. Following the above acquisitions. Truecaller's holding of own shares amounts to 27,904,571 B shares and 5,600,000 C-shares as of 28 March 2024, which corresponds to 8.79% of the outstanding capital. The total number of shares in Truecaller. including own shares. is 381,187,529 and the number of outstanding shares. excluding the own shares. is 347,682,958.

For more information, please contact:
Andreas Frid, Head of IR & Communication
+46 705 29 08 00
[email protected]

About Truecaller:

Truecaller (TRUE B) is the leading global platform for verifying contacts and blocking unwanted communication. We enable safe and relevant conversations between people and make it efficient for businesses to connect with consumers. Fraud and unwanted communication are endemic to digital economies. especially in emerging markets. We are on a mission to build trust in communication. Truecaller is an essential part of everyday communication for more than 374 million active users, with more than a billion downloads since launch and around 50 billion unwanted calls identified and blocked in 2022. Headquartered in Stockholm. since 2009. we are a co-founder led. entrepreneurial company. with a highly experienced management team. Truecaller is listed on Nasdaq Stockholm since 8 October 2021. For more information. please visit corporate.truecaller.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/truecaller-ab/r/repurchase-of-truecaller-b-shares-in-week-13--2024,c3954847

The following files are available for download:

https://mb.cision.com/Main/20429/3954847/2705252.pdf

Press release buybacks week 13 2024 Truecaller

 

SOURCE Truecaller AB


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 10:15
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 06:47
After tens of thousands of NYC children were turned away from "Summer Rising," New York City's popular, free summer enrichment program, Brains & Motion launched a campaign offering camps at NYU for a small fraction of the up-to-$1400 per week price...



News published on and distributed by: